Ixekizumab

Phase 1Completed

1 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Healthy

Conditions

Healthy

Trial Timeline

Jan 29, 2019 → Jun 7, 2019

NCT ID

NCT03848416

About Ixekizumab

Ixekizumab is a phase 1 stage product being developed by Eli Lilly for Healthy. The current trial status is completed. This product is registered under clinical trial identifier NCT03848416. Target conditions include Healthy.

What happened to similar drugs?

20 of 20 similar drugs in Healthy were approved

Approved (20) Terminated (1) Active (0)

✅mRNA-1273.712ModernaApproved

✅Cholestyramine + Colesevelam HClDaiichi SankyoApproved

✅Cholestyramine + Cholestyramine + TangDaiichi SankyoApproved

✅Olmesartan medoxomil + Irbesartan + ValsartanDaiichi SankyoApproved

✅Perampanel 6 MGEisaiApproved

✅eszopiclone, zolpidem, placeboSumitomo PharmaApproved

✅Listerine Experimental Mouthwash + Colgate Cavity Protection Toothpaste + Listerine Total Care ZeroJohnson & JohnsonApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (10)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05855967	Approved	Completed	Jun 27, 2023	Sep 23, 2024	Plaque Psoriasis
NCT04259346	Phase 1	Completed	Feb 5, 2020	Feb 19, 2021	Healthy
NCT03942042	Approved	Completed	Jul 5, 2019	Jul 22, 2020	Generalized Pustular Psoriasis
NCT03848416	Phase 1	Completed	Jan 29, 2019	Jun 7, 2019	Healthy
NCT03848403	Phase 1	Terminated	Jan 29, 2019	Jul 18, 2019	Healthy
NCT03485976	Phase 2	Completed	May 23, 2018	Jan 13, 2020	Pityriasis Rubra Pilaris
NCT03099538	Phase 2	Completed	Aug 15, 2017	Jun 6, 2019	Bullous Pemphigoid
NCT03137160	Phase 2	Completed	May 4, 2017	Aug 16, 2018	Pyoderma Gangrenosum
NCT03073213	Phase 1	Completed	Apr 13, 2017	May 14, 2019	Psoriasis
NCT02387801	Phase 3	Completed	Apr 1, 2015	Aug 1, 2016	Psoriasis

Competing Products

20 competing products in Healthy

See all competitors

Product	Company	Stage	Hype Score
Use of Wearable Digital Sensors After mRNA Vaccination in Adults	Moderna	Preclinical	0
mRNA-0184	Moderna	Phase 1	0
mRNA-6231	Moderna	Phase 1	0
Letrozole	Dr. Reddy's Laboratories	Phase 1	26
Isotretinoin	Dr. Reddy's Laboratories	Phase 1	26
Fexofenadine	Dr. Reddy's Laboratories	Phase 1	26
Sertraline	Dr. Reddy's Laboratories	Phase 1	26
Nizatidine + Axid	Dr. Reddy's Laboratories	Phase 1	26
Anastrozole	Dr. Reddy's Laboratories	Phase 1	26
mRNA-1273.712	Moderna	Approved	0
Risperidone	Dr. Reddy's Laboratories	Phase 1	26
Lamotrigine	Dr. Reddy's Laboratories	Phase 1	26
Metformin + Glucophage	Dr. Reddy's Laboratories	Phase 1	26
Lamotrigine	Dr. Reddy's Laboratories	Phase 1	26
mRNA-0184	Moderna	Phase 1	0
Divalproex Sodium	Dr. Reddy's Laboratories	Phase 1	26
Sirolimus	Dr. Reddy's Laboratories	Phase 1	26
Glimepiride	Dr. Reddy's Laboratories	Phase 1	26
Ziprasidone Hydrochloride	Dr. Reddy's Laboratories	Phase 1	26
Naproxen sodium	Dr. Reddy's Laboratories	Phase 1	26